Generic name: Triumeq is a combination of the drugs lamivudine, or 3TC, dolutegravir and abacavir.
Brand names: Triumeq
Class: Complete combination tablets
Very common (affecting more than 1 in 10 people): Diarrhoea, headache, nausea, fatigue, insomnia.Common (affecting up to 1 in 10 people): Hypersensitivity reaction (which can be caused by abacavir or douletegravir)*, rash, itching, vomiting, appetite loss, stomach pain or discomfort, indigestion, flatulence, dizziness, nightmares or abnormal dreams, tiredness, depression, fever, runny nose, hair loss, joint pain, muscle pain and discomfort, weakness, feeling generally unwell, cough, increased levels of liver enzymes. Uncommon (affecting up to 1 in 100 people): Inflammation of the liver, suicidal thoughts/behaviours (especially in people who have previously had depression or mental health problems), thrombocytopenia (a decrease in the number of cells which are involved with clotting of the blood), anaemia, neutropenia, increased levels of triglycerides in the blood, an increase in blood levels of glucose.
One tablet once a day.
Take with or without food.
*If you're planning to take Triumeq, or any treatment containing abacavir, your doctor should carry out a blood test for a gene called HLA-B*5701. You're more likely to have a hypersensitivity reaction to abacavir if you have this gene. If the test shows that you do have the gene, you should not take Triumeq, or any other treatment containing abacavir.
Last reviewed on 10/01/2017 Next review: 10/01/2020
Any questions? Email firstname.lastname@example.org Information included on this website was correct at the time of publication.
Data and image supplied by NAM.
Various people talk about their experiences of living with HIV.
CAB - Citizens Advice Bureau
HIV Drug Interactions
George House Trust
Equality and Human Rights Commission
Copyright 2018 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527)
Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 314-320 Gray's Inn Road, London, WC1X 8DP.